Yüklüyor......
ASSESSING THE IMPACT OF SAFETY MONITORING ON THE EFFICACY ANALYSIS IN LARGE PHASE III GROUP SEQUENTIAL TRIALS WITH NON-TRIVIAL SAFETY EVENT RATE
In Phase III clinical trials for life-threatening conditions, some serious but expected adverse events, such as early deaths or congestive heart failure, are often treated as the secondary or co-primary endpoint, and are closely monitored by the data and safety monitoring committee. A naïve group se...
Kaydedildi:
Yayımlandı: | J Biopharm Stat |
---|---|
Asıl Yazarlar: | , , , |
Materyal Türü: | Artigo |
Dil: | Inglês |
Baskı/Yayın Bilgisi: |
2015
|
Konular: | |
Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4661138/ https://ncbi.nlm.nih.gov/pubmed/26010228 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10543406.2015.1052473 |
Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|